Checkmate Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Checkmate Pharmaceuticals's estimated annual revenue is currently $2.6M per year.
- Checkmate Pharmaceuticals's estimated revenue per employee is $219,583
Employee Data
- Checkmate Pharmaceuticals has 12 Employees.
- Checkmate Pharmaceuticals grew their employee count by -14% last year.
Checkmate Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | MSAT, Investigations | Reveal Email/Phone |
4 | General Counsel | Reveal Email/Phone |
Checkmate Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 1 | -50% | N/A | N/A |
#3 | $5.1M | 33 | 22% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 2 | -60% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 11 | 10% | N/A | N/A |
#10 | $5.4M | 29 | 0% | N/A | N/A |
What Is Checkmate Pharmaceuticals?
Checkmate Pharmaceuticals is a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$2.6M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Checkmate Pharmaceuticals News
2022-04-20 - Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major ...
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Global Strategic Fund I. Venbio Sells 27,668 Shares. Posted by admin on Apr 26th...
2022-04-19 - Regeneron forks out $250m to buy Checkmate - BioProcess ...
Regeneron will increase its research efforts in immuno-oncology through the all-cash acquisition of Checkmate Pharmaceuticals.
2022-04-13 - Regeneron buys Checkmate Pharmaceuticals for $250M cash
Regeneron plans to show there is more to skin cancer than PD-1 inhibitors through the $250 million acquisition of Checkmate Pharmaceuticals...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.3M | 12 | -8% | $8.1M |
#2 | $0.5M | 12 | -8% | $9.1M |
#3 | $2M | 12 | -8% | $1M |
#4 | $2.5M | 12 | -29% | N/A |
#5 | $3.5M | 12 | 0% | $16.4M |